Justin Odegaard

Discover how biopharma researchers and clinical oncologists are harnessing the power of novel epigenomic biomarkers to pinpoint the right patients most likely to benefit from your therapy refining your therapeutic strategies and ultimately bringing more effective medicine to the patients who need them.